Facebook
Twitter
LinkedIn
ForwardMiami Cancer Institute Multispecialty Grand Rounds: Proton Craniospinal Irradiation for Leptomeningeal Metastasis – Where are we Heading?
Leptomeningeal metastases (LM) are associated with limited survival and treatment options. While involved-field radiotherapy is effective for local palliation, it lacks durability. We evaluated the toxicities of proton craniospinal irradiation (CSI), a treatment encompassing the entire central nervous system (CNS) compartment, for patients with LM from solid tumors.
Target Audience
Oncologists, Radiation Oncologists, Hematology Oncologists, Radiation Therapists, Endocrinologists, Pulmonologists, Otolaryngologists, General Surgeons, General Practitioners, Obstetricians and Gynecologists, Nurses, Social Workers, Patient Navigators and all other interested healthcare professionals.
Learning Objectives
- Implement hypofractionated proton CSI using proton therapy for patients with LM from solid tumors.
- Evaluate toxicities of proton craniospinal irradiation (CSI) for patients with LM from solid tumors.
Jonathan Yang, M.D.
Associate Professor
Director of Metastatic Disease and Developmental Therapeutics
Department of Radiation Oncology
University of Washington
Seattle, Washington
Jonathan Yang, M.D., faculty for this educational activity, has done research for Debiopharma, AstraZeneca, Kazia Therapeutics and X-Rad Therapeutics. He is a consultant for Galera Therapeutics, Kazia Therapeutics and Plus Therapeutics. He is and advisor for Nanocan Therapeutics. He has stocks/stock Options with Nanocan Therapeutics and has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.
Guilherme Rabinowits, M.D., conference series director, has indicated that he is an advisor with Sanofi-Genzyme, Regeneron, Castle and Boston Gene. All of the relevant financial relationships listed for this individual have been mitigated.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationship(s) to disclose with ineligible companies*
*Ineligible companies - Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been approved for 1 credit hour, CE Broker Course #20-680158, by the Florida Boards of Medicine, Osteopathic Medicine and by the Florida Council of Physician Assistants.
This activity has also been approved for 1 credit hour for Nurse Practitioners, Nurses. Baptist Health South Florida CE Broker Provider #50-182.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 General certificate of attendance
- 1.00 Nurse Practitioners
- 1.00 Florida Board of Nursing
Required Hardware/Software
 | PC/Mac UsersThis site is supported on the most recent stable releases of the following browsers:
| ||||||
 | Mobile UsersThis site is supported on the following mobile devices:
| ||||||
 | Technical SupportIf you are experiencing technical difficulties or have received an error message, please send an email to [email protected] and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours. |
